entacapone
E804592
Parkinson’s disease medication
catechol-O-methyltransferase inhibitor
nitrocatechol derivative
pharmaceutical drug
small molecule
Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct medication in Parkinson’s disease therapy to prolong and enhance the effects of levodopa.
All labels observed (1)
| Label | Occurrences |
|---|---|
| entacapone canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9524766 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: entacapone Context triple: [levodopa, oftenCombinedWith, entacapone]
-
A.
levodopa
Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
-
B.
Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
-
C.
pimozide
Pimozide is a typical antipsychotic medication primarily used to treat Tourette’s disorder and severe tics.
-
D.
Acurenam
Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: entacapone Target entity description: Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct medication in Parkinson’s disease therapy to prolong and enhance the effects of levodopa.
-
A.
levodopa
Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
-
B.
Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
-
C.
pimozide
Pimozide is a typical antipsychotic medication primarily used to treat Tourette’s disorder and severe tics.
-
D.
Acurenam
Acurenam is a town located in the Centro Sur province of Equatorial Guinea.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
Parkinson’s disease medication
ⓘ
catechol-O-methyltransferase inhibitor ⓘ nitrocatechol derivative ⓘ pharmaceutical drug ⓘ small molecule ⓘ |
| canBeCombinedInFixedDoseWith |
carbidopa
NERFINISHED
ⓘ
levodopa ⓘ |
| componentOfBrand | Stalevo NERFINISHED ⓘ |
| developedBy | Orion Corporation NERFINISHED ⓘ |
| doesNotCross | blood–brain barrier effectively ⓘ |
| enhancesEffectOf |
carbidopa/levodopa combination
ⓘ
levodopa ⓘ |
| hasAdverseEffect |
abdominal pain
ⓘ
diarrhea ⓘ dyskinesia ⓘ fatigue ⓘ hallucination ⓘ nausea ⓘ orthostatic hypotension ⓘ urine discoloration ⓘ vomiting ⓘ |
| hasATCCode | N04BX02 ⓘ |
| hasBrandName |
Comtan
NERFINISHED
ⓘ
Comtess NERFINISHED ⓘ |
| hasColorEffectOnUrine | brownish-orange discoloration GENERATED ⓘ |
| hasContraindication |
history of neuroleptic malignant syndrome
ⓘ
history of non-traumatic rhabdomyolysis ⓘ pheochromocytoma ⓘ |
| hasIUPACName | (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction | reversible inhibition of catechol-O-methyltransferase ⓘ |
| hasMolecularFormula | C14H15N3O5 ⓘ |
| hasPharmacologicalClass | COMT inhibitor ⓘ |
| hasProteinBinding | high protein binding ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasTarget | peripheral COMT ⓘ |
| increases |
ON time in Parkinson’s disease patients on levodopa
ⓘ
duration of levodopa effect ⓘ plasma concentration of levodopa ⓘ |
| indicatedFor |
Parkinson’s disease
NERFINISHED
ⓘ
management of end-of-dose motor fluctuations in Parkinson’s disease ⓘ |
| inhibits | catechol-O-methyltransferase ⓘ |
| marketedBy | Novartis NERFINISHED ⓘ |
| metabolizedBy | glucuronidation ⓘ |
| reduces |
OFF time in Parkinson’s disease patients on levodopa
ⓘ
peripheral metabolism of levodopa ⓘ |
| takenWith | each dose of levodopa/carbidopa ⓘ |
| usedAs | adjunct to levodopa therapy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: entacapone Description of subject: Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct medication in Parkinson’s disease therapy to prolong and enhance the effects of levodopa.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.